Lecia Sequist, MD, an oncologist at Mass General, says, “Many people I meet are shocked to learn that lung cancer is the deadliest of all cancers, responsible for over a quarter of all cancer-related deaths. In fact, more individuals die from lung cancer each year than die of colorectal, breast, pancreatic and prostate cancers combined.” Despite its tragic impact on thousands of patients and families every year, there is a critical gap in funding for lung cancer research — but the LUNGevity Foundation is changing that.
Lung cancer often develops and spreads before patients can even notice symptoms. LUNGevity aims to support the development of early detection methodologies to catch lung cancer at an early stage, thus increasing the odds of survival. LUNGevity has supported 100 research projects across 23 states since 2001 and is currently the largest private funder of lung-cancer focused research in the country, ensuring that lab studies and trials move more quickly into applicable therapies and treatments for patients. LUNGevity’s goal is to ensure patients have the right treatment available at the right time to ensure the best quality of life and survival.
LUNGevity is a tribute to the hard work of lung cancer researchers and physicians and the many donors who partner with them to ensure brighter futures for lung cancer patients and their families.”
